Nucleic acid drugs, particularly RNA interference (RNAi) drugs, stand at the forefront of the third wave in pharmaceutical innovation, following small molecules and antibodies. Valued for their precision in gene silencing, favorable safety profiles, and straightforward synthesis process, RNAi drugs are transforming therapies for chronic and rare diseases. This study deciphers the global landscape of RNAi drug patents, showcasing the trends in patent applications, key applicants, and explorations in technical domains, while highlighting cutting-edge advancements. From breakthroughs in sequence design and chemical modifications to next-generation delivery systems, this analysis reveals the key technologies dominating the patent landscape. As biotech leaders and emerging innovators compete in this field, understanding these trends and core technologies is critical for navigating intellectual property challenges and accelerating drug development. This comprehensive analysis not only highlights the future potential of RNAi therapies but also serves as a strategic guide for innovators aiming to lead the next frontier of precision medicine.
Li, X. et al. / J. Chin. Pharm. Sci. 2025, 34 (8), 701–714.
>
>